The dark side of PD-1 receptor inhibition
Authors:
Open Access
- 15 November 2017
- journal article
- editorial
- Published by Springer Nature in Nature
- Vol. 552 (7683) , 41-42
Abstract
Inhibiting the protein PD-1 can activate T cells that trigger immune responses against tumour cells. But it emerges that, in mice, this immunotherapy exacerbates a cancer that involves the T cells themselves. See Letter p.121 PD-1 functions as an inhibitory receptor in the immune system and is a target of cancer immunotherapy. Jürgen Ruland and colleagues now show that PD-1 also functions as a tumour suppressor that is often lost in human T cell lymphomas. Experimentally, loss of PD-1 promotes the development of T cell non-Hodgkin lymphomas by modulating oncogenic signalling pathways. Blocking these pathways reduces tumorigenesis. These findings may have implications for T cell lymphoma therapies.Keywords
This publication has 8 references indexed in Scilit:
- PD-1 is a haploinsufficient suppressor of T cell lymphomagenesisNature, 2017
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2017
- Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint BlockadeCell, 2017
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunityNature, 2017
- The emerging role of immune checkpoint inhibition in malignant lymphomaHaematologica, 2016
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyJournal of Clinical Oncology, 2016
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Serine-threonine kinases in TCR signalingNature Immunology, 2014